AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Friday, May 12th.
According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
A number of other analysts have also commented on the company. Maxim Group reaffirmed a “buy” rating and issued a $11.00 target price on shares of AEterna Zentaris in a research report on Thursday, March 30th. HC Wainwright decreased their price objective on AEterna Zentaris from $7.50 to $3.00 and set a “buy” rating for the company in a report on Wednesday, May 10th.
AEterna Zentaris (NASDAQ AEZS) traded down 5.1373% during trading on Friday, reaching $0.9676. The company’s stock had a trading volume of 348,941 shares. The firm’s market cap is $13.87 million. AEterna Zentaris has a 52 week low of $0.78 and a 52 week high of $5.59. The stock’s 50 day moving average is $1.04 and its 200-day moving average is $2.59.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.02. AEterna Zentaris had a negative return on equity of 425.52% and a negative net margin of 2,732.69%. The business had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.85 million. During the same period in the previous year, the company posted ($0.37) EPS. The firm’s revenue was up 8.3% compared to the same quarter last year. On average, equities research analysts forecast that AEterna Zentaris will post ($1.39) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/06/17/zacks-investment-research-lowers-aeterna-zentaris-inc-aezs-to-sell-updated-updated-updated.html.
A hedge fund recently raised its stake in AEterna Zentaris stock. Morgan Stanley boosted its stake in shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 9.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 33,725 shares of the biopharmaceutical company’s stock after buying an additional 2,800 shares during the period. Morgan Stanley’s holdings in AEterna Zentaris were worth $102,000 as of its most recent SEC filing. 3.08% of the stock is owned by institutional investors and hedge funds.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about AEterna Zentaris Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AEterna Zentaris Inc. and related companies.